| HOME >> BIOLOGY >> TECHNOLOGY |
Royalties 3,956 - 3,956 -
License, collaboration
and other 22,237 10,093 23,003 13,354
Total revenues 51,620 25,408 74,431 40,658
Costs and expenses:
Cost of sales 4,351 2,392 7,734 3,949
Research and development 17,151 28,799 34,396 55,977
Selling, general and
administrative 35,342 46,504 67,792 88,952
Restructuring charges - 5,367 (7) 5,367
Total costs and expenses 56,844 83,062 109,915 154,245
Loss from operations (5,224) (57,654) (35,484) (113,587)
Other income (expense), net:
Interest and other income,
net 6,333 3,222 7,868 7,265
Interest expense (3,661) (3,166) (6,835) (6,332)
Total other income (expense),
net 2,672 56 1,033 933
Loss before income taxes (2,552) (57,598) (34,451) (112,654)
Income tax provision 1,742 - 1,742 -
Net loss $(4,294) $(57,598) $(36,193) $(112,654)
Basic and diluted net
loss per share $(0.07) $(0.97) $(0.60) $(1.91)
Shares used in computing
basic and diluted net
loss per share 60,856 59,223 60,706 59,089
Reconciliation of GAAP Items
to Non-GAAP Items:
Net loss, GAAP as reported $(4,294) $(57,598) $(36,193) $(112,654)
Adjustments:
Non-recurring stock-based
compensation charges - 13,186 - 13,186
Restructuring ch
'/>"/>
| SOURCE CV Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |